An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance - Full Text View

Purpose

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Condition	Intervention	Phase
Glaucoma Ocular Hypertension	Drug: travoprost, latanoprost, or bimatoprost Drug: Additional ocular hypotensive medication	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic
Official Title:	An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Blood Pressure Medicines Glaucoma High Blood Pressure

U.S. FDA Resources

Further study details as provided by Robin, Alan L., M.D.:

Primary Outcome Measures:

Compliance.


Estimated Enrollment:	60
Study Start Date:	December 2005
Estimated Study Completion Date:	April 2006

Detailed Description:

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Currently using one or two topical ocular hypotensive medications

Exclusion Criteria:

Hypersensitivity to any component of medication

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00329095

Sponsors and Collaborators

Robin, Alan L., M.D.

Investigators


Principal Investigator:	Alan L. Robin, MD	Alan L. Robin, M.D.

More Information

No publications provided by Robin, Alan L., M.D.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007 Oct;144(4):533-40. Epub 2007 Aug 8.


ClinicalTrials.gov Identifier:	NCT00329095 History of Changes
Other Study ID Numbers:	GMED-01
Study First Received:	May 19, 2006
Last Updated:	May 22, 2006
Health Authority:	United States: Institutional Review Board

Keywords provided by Robin, Alan L., M.D.:


Glaucoma Compliance

Additional relevant MeSH terms:


Ocular Hypertension Eye Diseases Antihypertensive Agents	Cardiovascular Agents Pharmacologic Actions Therapeutic Uses

ClinicalTrials.gov processed this record on March 03, 2015